Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most ...

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares ...

Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

Check the time stamp on this data. Updated AI-Generated Signals for Halozyme Therapeutics Inc. (HALO) available here: HALO.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...